MQS Management LLC Acquires Shares of 2,409 Cencora, Inc. $COR

MQS Management LLC acquired a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,409 shares of the company’s stock, valued at approximately $814,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oakworth Capital Inc. purchased a new stake in Cencora in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new stake in Cencora in the fourth quarter valued at approximately $27,000. Archer Investment Corp lifted its stake in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the last quarter. Optima Capital LLC purchased a new stake in Cencora in the fourth quarter valued at approximately $31,000. Finally, IAG Wealth Partners LLC purchased a new stake in Cencora in the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 3.6%

NYSE:COR opened at $275.01 on Friday. The stock has a fifty day moving average price of $305.70 and a two-hundred day moving average price of $336.77. The stock has a market capitalization of $53.51 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 1.22 and a beta of 0.64. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Cencora announced that its board has authorized a stock buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research firms have recently commented on COR. JPMorgan Chase & Co. upped their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Barclays upped their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Morgan Stanley set a $342.00 price target on Cencora in a research note on Friday, May 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Robert W. Baird cut their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.